Compass Therapeutics ( NASDAQ: CMPX ) has appointed Thomas Schuetz, President of Research and Development and Vice Chair of the Board of the company, as President and Chief Executive Officer, effective May 28, 2024. Vered Bisker-Leib, has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Bisker-Leib will continue to be available to the company as a Senior Consultant for the next 15 months.
Source: Press Release More on Compass Therapeutics Compass gains FDA Fast Track status for biliary tract cancer candidate Compass Therapeutics reports FY results Seeking Alpha’s Quant Rating on Compass Therapeutics Historical earnings data for Compass Therapeutics Financial information for Compass Therapeutics.
